

TD Health Sciences Fund

532180
(03/25)

TD Mutual Funds Annual Financial Statements

for the period ended December 31, 2024



Management's Responsibility for Financial Reporting

The accompanying financial statements have been prepared by TD Asset Management Inc. ("TDAM"), as manager of the TD Mutual Fund Trusts, TD Managed Assets Program Portfolios and TD Managed ETF Portfolios (collectively the "Funds" and individually the "Fund") and approved by TDAM's board of directors. The manager is responsible for the integrity, objectivity and reliability of the data presented. This responsibility includes selecting appropriate accounting principles and making judgments and estimates consistent with *International Financial Reporting Standards as issued by the International Accounting Standards Board* ("IFRS"). The manager is also responsible for the development of internal controls over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced, and the safeguarding of all assets of the Funds.

The board of directors of TDAM is responsible for reviewing and approving the financial statements and overseeing management's performance of its financial reporting responsibilities.

Ernst & Young LLP is the external auditor of the Funds. The auditor has audited the financial statements in accordance with Canadian generally accepted auditing standards to enable it to express their opinion on the financial statements. The auditor's report is included on the following page of this annual report.

On behalf of TDAM, manager of the Funds.



Bruce Cooper
Director and
Chief Executive Officer
March 14, 2025



Len Kroes
Chief Financial Officer
March 14, 2025

Independent Auditor's Report

To the Unitholders and Trustee of:

TD Canadian Money Market Fund
 TD Premium Money Market Fund
 TD U.S. Money Market Fund
 TD Target 2025 Investment Grade Bond Fund
 TD Target 2026 Investment Grade Bond Fund
 TD Target 2027 Investment Grade Bond Fund
 TD Target 2025 U.S. Investment Grade Bond Fund
 TD Target 2026 U.S. Investment Grade Bond Fund
 TD Target 2027 U.S. Investment Grade Bond Fund
 TD Ultra Short Term Bond Fund
 TD Short Term Bond Fund
 TD Canadian Bond Fund
 TD Income Advantage Portfolio
 TD Canadian Core Plus Bond Fund
 TD Canadian Corporate Bond Fund
 TD U.S. Corporate Bond Fund
 TD Canadian Long Term Federal Bond Fund
 TD U.S. Long Term Treasury Bond Fund
 TD North American Sustainability Bond Fund
 TD Global Income Fund
 TD Global Core Plus Bond Fund
 TD Global Unconstrained Bond Fund
 TD High Yield Bond Fund
 TD Preferred Share Fund
 TD Global Conservative Opportunities Fund
 TD Global Balanced Opportunities Fund
 TD Monthly Income Fund
 TD Tactical Monthly Income Fund
 TD North American Sustainability Balanced Fund
 TD U.S. Monthly Income Fund
 TD U.S. Monthly Income Fund - C\$
 TD Diversified Monthly Income Fund
 TD Global Tactical Monthly Income Fund
 TD Balanced Growth Fund
 TD Dividend Income Fund
 TD Canadian Diversified Yield Fund
 TD Canadian Low Volatility Fund
 TD Dividend Growth Fund
 TD Canadian Blue Chip Dividend Fund
 TD Canadian Large-Cap Equity Fund
 TD Canadian Equity Fund
 TD Canadian Small-Cap Equity Fund

TD U.S. Low Volatility Fund
 TD North American Dividend Fund
 TD North American Sustainability Equity Fund
 TD U.S. Dividend Growth Fund
 TD U.S. Shareholder Yield Fund
 TD U.S. Equity Focused Fund
 TD U.S. Equity Focused Currency Neutral Fund
 TD U.S. Large-Cap Value Fund
 TD U.S. Capital Reinvestment Fund
 TD U.S. Disciplined Equity Alpha Fund TM
(formerly TD U.S. Quantitative Equity Fund)
 TD U.S. Equity Pool
 TD U.S. Mid-Cap Growth Fund
 TD U.S. Mid-Cap Growth Currency Neutral Fund
 TD U.S. Small-Cap Equity Fund
 TD Global Low Volatility Fund
 TD Global Shareholder Yield Fund
 TD Global Disciplined Equity Alpha Fund TM
 TD Global Equity Focused Fund
 TD Global Capital Reinvestment Fund
(formerly Epoch Global Equity Fund and TD Global Equity Growth Fund)
 TD International Equity Focused Fund
 TD International Equity Fund
 TD China Income & Growth Fund
 TD Emerging Markets Fund
 TD Resource Fund
 TD Precious Metals Fund
 TD Global Entertainment & Communications Fund
 TD Science & Technology Fund
 TD Health Sciences Fund
 TD Canadian Bond Index Fund
 TD Balanced Index Fund
 TD Canadian Index Fund
 TD Dow Jones Industrial Average Index Fund
 TD U.S. Index Fund
 TD U.S. Index Currency Neutral Fund
 TD Nasdaq® Index Fund
 TD International Index Fund
 TD International Index Currency Neutral Fund
 TD European Index Fund
 TD Global Technology Leaders Index Fund
 TD US\$ Retirement Portfolio
 TD Retirement Conservative Portfolio
 TD Retirement Balanced Portfolio

TD Comfort Conservative Income Portfolio
 TD Comfort Balanced Income Portfolio
 TD Comfort Balanced Portfolio
 TD Comfort Balanced Growth Portfolio
 TD Comfort Growth Portfolio
 TD Comfort Aggressive Growth Portfolio
 TD Fixed Income Pool
 TD Risk Management Pool
 TD Canadian Equity Pool
 TD Global Equity Pool
 TD Tactical Pool
 TD Alternative Risk Focused Pool
 TD Alternative Commodities Pool
 TD Alternative Long/Short Commodities Pool
 TD Managed Income Portfolio
 TD Managed Income & Moderate Growth Portfolio
 TD Managed Balanced Growth Portfolio
 TD Managed Aggressive Growth Portfolio
 TD Managed Maximum Equity Growth Portfolio
 TD FundSmart Managed Income & Moderate Growth Portfolio
 TD FundSmart Managed Balanced Growth Portfolio
 TD FundSmart Managed Aggressive Growth Portfolio
 TD Managed Income ETF Portfolio
 TD Managed Income & Moderate Growth ETF Portfolio
 TD Managed Balanced Growth ETF Portfolio
 TD Managed Aggressive Growth ETF Portfolio
 TD Managed Maximum Equity Growth ETF Portfolio
 (collectively, the "Funds")

Independent Auditor's Report

Opinion

We have audited the financial statements of the Funds, which comprise the statements of financial position as at December 31, 2024 and 2023 (as applicable), and the statements of comprehensive income, statements of changes in net assets attributable to holders of redeemable units and statements of cash flows for the periods then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Funds as at December 31, 2024 and 2023 (as applicable), and their financial performance and their cash flows for the periods then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Funds in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Management is responsible for the other information. The other information comprises the Management Report of Fund Performance of the Funds.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information, and in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

We obtained the Management Report of Fund Performance of the Funds prior to the date of this auditor's report. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact in this auditor's report. We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Funds' ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Funds or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Funds' financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Funds' internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Funds' ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Funds to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Ernst & Young LLP

Chartered Professional Accountants
Licensed Public Accountants
Toronto, Canada
March 14, 2025

TD Health Sciences Fund

Statements of Financial Position (in 000s except per unit amounts) as at December 31, 2024 and 2023

	2024	2023
Assets		
Current Assets		
Investments	\$ 1,571,683	\$ 1,662,937
Derivative Assets (Note 3)	2,306	305
Cash	6,881	28,122
Interest and Dividends Receivables	546	682
Subscriptions Receivable	584	1,022
Receivable for Investments Sold	0	1,350
	1,582,000	1,694,418
Liabilities		
Current Liabilities		
Unrealized Depreciation on Unfunded Commitments	0	0
Bank Overdraft	0	0
Accrued Liabilities	156	331
Redemptions Payable	2,542	2,610
Payable for Investments Purchased	195	2,124
	2,893	5,065
Net Assets Attributable to Holders of Redeemable Units	\$ 1,579,107	\$ 1,689,353
Net Assets Attributable to Holders of Redeemable Units – Per Series (Note 5)		
Investor Series	\$ 303,934	\$ 366,904
Advisor Series	\$ 236,550	\$ 253,304
F-Series	\$ 752,508	\$ 780,764
D-Series	\$ 283,794	\$ 286,785
O-Series	\$ 2,321	\$ 1,596
	\$ 1,579,107	\$ 1,689,353
Net Assets Attributable to Holders of Redeemable Units – Per Series Unit		
Investor Series	\$ 117.68	\$ 108.82
Advisor Series	\$ 56.47	\$ 52.21
F-Series	\$ 79.34	\$ 72.39
D-Series	\$ 21.14	\$ 19.33
O-Series	\$ 11.69	\$ 10.52

Statements of Comprehensive Income (in 000s except per unit amounts) for the periods ended December 31, 2024 and 2023

	2024	2023
Income		
Net Gain (Loss) on Investments and Derivatives		
Dividend Income	\$ 11,103	\$ 12,822
Interest for Distribution Purposes	403	427
Net Realized Gain (Loss)	187,659	125,304
Net Change in Unrealized Appreciation (Depreciation)	(9,814)	(110,913)
Net Gain (Loss) on Investments and Derivatives	189,351	27,640
Net change in Unrealized Appreciation (Depreciation) on Unfunded Commitments	0	0
Foreign Exchange Gain (Loss) on Cash and Other Net Assets	384	(212)
Securities Lending Income	189	287
Total Income (Loss)	189,924	27,715
Expenses (Note 6)		
Management Fees	30,822	32,236
Administration Fees	2,032	2,136
Independent Review Committee Fees	2	2
Interest Charges	48	17
Transaction Costs	472	379
Total Expenses before Waivers	33,376	34,770
Less: Waived Expenses	(48)	(17)
Total Net Expenses	33,328	34,753
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units before Tax	156,596	(7,038)
Tax Reclaims (Withholding Taxes)	(1,496)	(1,857)
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	\$ 155,100	\$ (8,895)
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Per Series		
Investor Series	\$ 31,277	\$ (5,666)
Advisor Series	\$ 21,161	\$ (3,578)
F-Series	\$ 75,500	\$ 346
D-Series	\$ 26,971	\$ (25)
O-Series	\$ 191	\$ 28
	\$ 155,100	\$ (8,895)
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Per Series Unit		
Investor Series	\$ 10.57	\$ (1.52)
Advisor Series	\$ 4.71	\$ (0.68)
F-Series	\$ 7.43	\$ 0.03
D-Series	\$ 1.91	\$ 0.00
O-Series	\$ 1.08	\$ 0.28

The accompanying notes are an integral part of the financial statements.

TD Health Sciences Fund

Statements of Changes in Net Assets Attributable to Holders of Redeemable Units (in 000s)

for the periods ended December 31, 2024 and 2023

	Investor Series		Advisor Series		F-Series	
	2024	2023	2024	2023	2024	2023
Net Assets Attributable to Holders of Redeemable Units at Beginning of the Period	\$ 366,904	\$ 449,046	\$ 253,304	\$ 292,678	\$ 780,764	\$ 884,115
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	31,277	(5,666)	21,161	(3,578)	75,500	346
Distributions to Holders of Redeemable Units						
From Net Investment Income	0	0	0	0	0	0
From Net Realized Gains	0	0	0	0	0	0
	0	0	0	0	0	0
Redeemable Unit Transactions						
Proceeds from Redeemable Units Issued	11,087	13,834	31,614	23,818	133,387	106,393
Reinvestments of Distributions	0	0	0	0	0	0
Redemption of Redeemable Units	(105,334)	(90,310)	(69,529)	(59,614)	(237,143)	(210,090)
Net Increase (Decrease) from Redeemable Unit Transactions	(94,247)	(76,476)	(37,915)	(35,796)	(103,756)	(103,697)
Net Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	(62,970)	(82,142)	(16,754)	(39,374)	(28,256)	(103,351)
Net Assets Attributable to Holders of Redeemable Units at End of the Period	\$ 303,934	\$ 366,904	\$ 236,550	\$ 253,304	\$ 752,508	\$ 780,764
Redeemable Unit Transactions						
Redeemable Units Outstanding, Beginning of the Period	3,372	4,087	4,851	5,551	10,786	12,254
Redeemable Units Issued	93	129	554	463	1,672	1,505
Redeemable Units Issued on Reinvestments	0	0	0	0	0	0
Redeemable Units Redeemed	(882)	(844)	(1,216)	(1,163)	(2,973)	(2,973)
Redeemable Units Outstanding, End of the Period	2,583	3,372	4,189	4,851	9,485	10,786
Weighted Average Units Outstanding	2,958	3,720	4,490	5,280	10,167	11,676

	D-Series		O-Series		TOTAL	
	2024	2023	2024	2023	2024	2023
Net Assets Attributable to Holders of Redeemable Units at Beginning of the Period	\$ 286,785	\$ 310,295	\$ 1,596	\$ N/A	\$ 1,689,353	\$ 1,936,134
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	26,971	(25)	191	28	155,100	(8,895)
Distributions to Holders of Redeemable Units						
From Net Investment Income	0	0	0	0	0	0
From Net Realized Gains	0	0	0	0	0	0
	0	0	0	0	0	0
Redeemable Unit Transactions						
Proceeds from Redeemable Units Issued	18,501	15,263	890	1,609	195,479	160,917
Reinvestments of Distributions	0	0	0	0	0	0
Redemption of Redeemable Units	(48,463)	(38,748)	(356)	(41)	(460,825)	(398,803)
Net Increase (Decrease) from Redeemable Unit Transactions	(29,962)	(23,485)	534	1,568	(265,346)	(237,886)
Net Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	(2,991)	(23,510)	725	1,596	(110,246)	(246,781)
Net Assets Attributable to Holders of Redeemable Units at End of the Period	\$ 283,794	\$ 286,785	\$ 2,321	\$ 1,596	\$ 1,579,107	\$ 1,689,353
Redeemable Unit Transactions						
Redeemable Units Outstanding, Beginning of the Period	14,836	16,075	152	N/A		
Redeemable Units Issued	865	808	76	156		
Redeemable Units Issued on Reinvestments	0	0	0	0		
Redeemable Units Redeemed	(2,276)	(2,047)	(30)	(4)		
Redeemable Units Outstanding, End of the Period	13,425	14,836	198	152		
Weighted Average Units Outstanding	14,118	15,513	177	100		

The accompanying notes are an integral part of the financial statements.

TD Health Sciences Fund

Statements of Cash Flows (in 000s)

for the periods ended December 31, 2024 and 2023

	2024	2023
Cash Flows from (used in) Operating Activities		
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	\$ 155,100	\$ (8,895)
Adjustment For:		
Accretion of Interest	(191)	(210)
Unrealized Foreign Exchange (Gain) Loss on Cash	4	(8)
Net Realized (Gain) Loss	(187,659)	(125,304)
Net Change in Unrealized (Appreciation) Depreciation	9,814	110,913
Net Change in Unrealized (Appreciation) Depreciation on Unfunded Commitments	0	0
Purchase of Investments and Derivatives	(1,707,868)	(1,858,934)
Proceeds from Sale, Paydown and Maturity of Investments and Derivatives	1,974,578	2,121,977
(Increase) Decrease in Interest and Dividends Receivables	136	8
Increase (Decrease) in Accrued Liabilities	(175)	36
Net Cash from (used in) Operating Activities	243,739	239,583
Cash Flows from (used in) Financing Activities		
Distributions Paid to Holders of Redeemable Units, Net of Reinvested Distributions	0	0
Proceeds from Issuance of Redeemable Units	156,078	124,777
Amounts Paid on Redemption of Redeemable Units	(421,054)	(362,288)
Net Cash from (used in) Financing Activities	(264,976)	(237,511)
Unrealized Foreign Exchange Gain (Loss) on Cash	(4)	8
Net Increase (Decrease) in Cash	(21,237)	2,072
Cash (Bank Overdraft) at Beginning of the Period	28,122	26,042
Cash (Bank Overdraft) at End of the Period	\$ 6,881	\$ 28,122
Interest for Distribution Purposes Received*, Net of Withholding Taxes	\$ 216	\$ 217
Dividends Received*, Net of Withholding Taxes	\$ 9,748	\$ 11,032

* Included as part of Cash Flows from (used in) Operating Activities.

The accompanying notes are an integral part of the financial statements.

TD Health Sciences Fund

Schedule of Investment Portfolio (in 000s except number of Shares or Units/Par Value) as at December 31, 2024

No. of Shares or Units/ Par Value	Description	Cost	Fair Value	No. of Shares or Units/ Par Value	Description	Cost	Fair Value
Biotechnology – 36.9%							
82,836	Agios Pharmaceuticals Inc.	\$ 4,584	\$ 3,913	23,795	Element Biosciences Inc., Conv. Pref., Series D, Private Placement	\$ 255	\$ 268
76,716	Akero Therapeutics Inc.	3,586	3,068	23,795	Element Biosciences Inc., Conv. Pref., Series D-1, Private Placement	255	268
232,656	Aktis Oncology Inc., Conv. Pref., Series B, Private Placement	1,262	1,338	168,358	Endeavor Biomedicines Inc., Conv. Pref., Series B, Private Placement	999	1,579
55,869	Alector Inc.	748	152	41,920	Endeavor Biomedicines Inc., Conv. Pref., Series C, Private Placement	375	393
110,865	Alkermes PLC	4,545	4,583	23,894	Entrada Therapeutics Inc.	624	594
272,694	Allogene Therapeutics Inc.	2,593	835	247,509	Exact Science Corporation, CMO Milestone, Private Placement	0	221
107,797	Alnylam Pharmaceuticals Inc.	22,005	36,462	123,755	Exact Science Corporation, FDA Milestone, Private Placement	0	110
63,742	Amgen Inc.	24,365	23,881	100,858	Exact Sciences Corporation	8,669	8,146
7,000	AnaptyBio Inc.	286	133	32,238	Fog Pharmaceuticals Inc., Conv. Pref., Series C, Private Placement	589	393
66,824	Annexon Inc.	514	493	54,075	Fog Pharmaceuticals Inc., Conv. Pref., Series D, Private Placement	776	571
19,346	Apellis Pharmaceuticals Inc.	1,550	887	26,803	Fog Pharmaceuticals Inc., Conv. Pref., Series E, Private Placement	226	240
63,223	Apogee Therapeutics Inc.	3,435	4,117	166,926	Fog Pharmaceuticals Inc., Private Placement	0	0
73,759	Arcellx Inc.	6,303	8,131	159,921	Generate Biomedicines Inc., Conv. Pref., Series B, Private Placement	2,378	2,724
65,954	argenx SE, ADR	25,060	58,305	32,577	Generate Biomedicines Inc., Conv. Pref., Series C, Private Placement	517	555
61,258	Arsenal Biosciences Inc., Conv. Pref., Series C, Private Placement	1,552	1,636	170,343	Generation Bio Company	4,144	260
84,826	Ascendis Pharma AS, ADR	15,832	16,787	59,614	Genesis Therapeutics Inc., Conv. Pref., Series A, Private Placement	396	438
34,515	Aura Biosciences Inc.	557	408	172,859	Genesis Therapeutics Inc., Conv. Pref., Series B, Private Placement	1,187	1,269
207,586	Avidity Biosciences Inc.	5,718	8,677	77,307	Geron Corporation	447	393
92,153	Beam Therapeutics Inc.	4,163	3,285	465,019	Gyroscope Therapeutics Holdings PLC, Milestone Payment 1, Private Placement	593	0
60,781	BeiGene Limited, ADR	16,887	16,138	309,908	Gyroscope Therapeutics Holdings PLC, Milestone Payment 2, Private Placement	395	0
51,210	Bicara Therapeutics Inc.	1,253	1,282	309,908	Gyroscope Therapeutics Holdings PLC, Milestone Payment 3, Private Placement	395	0
108,008	Bicycle Therapeutics PLC, ADR	3,550	2,174	32,645	Ideaya Biosciences Inc.	1,260	1,206
13,766	Biogen Inc.	4,871	3,026	82,236	IGM Biosciences Inc.	2,326	722
160,933	Biohaven Limited	6,263	8,640	51,260	Immatics NV	797	524
29,598	BioMarin Pharmaceutical Inc.	3,808	2,797	75,438	Immuneering Corporation, Class A	848	239
17,866	BioNTech SE, ADR	2,917	2,926	95,050	Immunocore Holdings PLC, ADR	6,600	4,031
230,766	Bluejay Therapeutics Inc., Conv. Pref., Series C, Private Placement	2,072	2,165	141,498	Immunome Inc.	2,504	2,160
141,264	Blueprint Medicines Corporation	14,567	17,711	44,100	Incyte Corporation	4,397	4,378
44,300	Cabaletta Bio Inc.	1,208	145	222,575	Insmed Inc.	11,300	22,089
103,114	Cargo Therapeutics Inc.	2,698	2,137	74,446	Ionis Pharmaceuticals Inc.	4,871	3,741
255,192	Caris Life Sciences Inc., Conv. Pref., Series C, Private Placement	934	1,805	92,639	Iovance Biotherapeutics Inc.	1,470	985
189,738	Caris Life Sciences Inc., Conv. Pref., Series D, Private Placement	1,859	1,342	39,418	Janux Therapeutics Inc.	2,901	3,034
54,039	Celldex Therapeutics Inc.	3,170	1,963	25,800	Keros Therapeutics Inc.	2,258	587
290,683	Centessa Pharmaceuticals PLC, ADR	5,321	6,999	83,200	Kodiak Sciences Inc.	646	1,190
39,592	CG Oncology Inc.	1,244	1,632	21,740	Krystal Biotech Inc.	4,444	4,896
663,909	Chroma Medicine Inc., Conv. Pref., Series I, Private Placement	1,927	954	114,280	Kymera Therapeutics Inc.	5,605	6,609
44,700	Climb Bio Inc.	408	116	45,121	Kyvera Therapeutics Inc.	1,216	243
12,100	Corbus Pharmaceuticals Holdings Inc.	731	205	53,996	Legend Biotech Corporation, ADR	4,156	2,526
99,712	Crinetix Pharmaceuticals Inc.	4,820	7,329	51,500	LENZ Therapeutics Inc.	1,715	2,137
52,560	Cytokinetics Inc.	4,081	3,554	502,321	Lyell Immunopharma Inc.	3,967	462
5,398	Day One Biopharmaceuticals Inc.	99	98	21,700	MacroGenics Inc.	536	101
275,887	Delfi Diagnostics Inc., Conv. Pref., Series A, Private Placement	725	1,921	13,165	Madrigal Pharmaceuticals Inc.	4,330	5,839
165,940	Delfi Diagnostics Inc., Conv. Pref., Series B, Private Placement	1,027	1,156	29,120	Merus NV	1,685	1,760
132,876	Denali Therapeutics Inc.	4,930	3,893	110,048	Monte Rosa Therapeutics Inc.	1,877	1,098
22,466	Disc Medicine Inc., Class A	1,698	2,047				
36,015	Dyne Therapeutics Inc.	1,569	1,220				
90,154	Eikon Therapeutics Inc., Conv. Pref., Series B, Private Placement	2,047	689				
17,359	Eikon Therapeutics Inc., Conv. Pref., Series C, Private Placement	504	133				
72,916	Element Biosciences Inc., Conv. Pref., Series C, Private Placement	1,853	1,016				

No. of Shares or Units/ Par Value	Description	Cost	Fair Value	No. of Shares or Units/ Par Value	Description	Cost	Fair Value
130,817	MoonLake Immunotherapeutics, Class A	\$ 7,263	\$ 10,183	418,977	Summit Therapeutics Inc.	\$ 11,078	\$ 10,747
44,084	Natera Inc.	8,142	10,031	93,315	Tenax Therapeutics Inc., Warrants Aug 6, 2029	0	137
84,221	National Resilience Inc., Conv. Pref., Series B, Private Placement	1,511	5,626	177,299	Tenax Therapeutics Inc., Pre-Funded Warrants, Private Placement	730	1,427
36,082	National Resilience Inc., Conv. Pref., Series C, Private Placement	1,941	2,410	35,025	Tessera Therapeutics Inc., Conv. Pref., Series C, Private Placement	910	1,030
45,282	Neurocrine Biosciences Inc.	7,297	8,885	235,774	Treeline Biosciences Inc., Conv. Pref., Series A-1, Private Placement	2,740	2,918
7,900	Neurogene Inc.	745	260	197,235	Treeline Biosciences Inc., Conv. Pref., Series A, Private Placement	2,049	2,441
88,298	Nutcracker Therapeutics Inc., Conv. Pref., Series C, Private Placement	1,197	1,365	46,742	Ultragenyx Pharmaceutical Inc.	3,777	2,827
21,833	Nuvalent Inc., Class A	2,916	2,457	22,700	United Therapeutics Corporation	10,116	11,513
398,177	Obsidian Therapeutics Inc., Conv. Pref., Series C, Private Placement	1,026	1,086	26,700	UroGen Pharma Limited	458	409
100,174	Odyssey Therapeutics Inc., Conv. Pref., Series B, Private Placement	818	749	90,934	Vaxcyte Inc.	8,403	10,700
9,193	Odyssey Therapeutics Inc., Conv. Pref., Series C, Private Placement	63	66	97,150	Vera Therapeutics Inc., Class A	4,780	5,906
73,900	ORIC Pharmaceuticals Inc.	1,094	857	65,544	Vertex Pharmaceuticals Inc.	18,509	37,941
47,538	Oruka Therapeutics Inc.	1,708	1,325	25,600	Viridian Therapeutics Inc.	847	705
26,449	Praxis Precision Medicines Inc.	2,030	2,926	57,465	Voyager Therapeutics Inc.	728	468
80,326	Prelude Therapeutics Inc.	1,450	147	56,361	Xencor Inc.	2,143	1,862
60,844	ProfoundBio Inc., Escrow Fund Payment, Private Placement	83	83	154,564	Zai Lab Limited, ADR	9,315	5,819
203	ProfoundBio Inc., Expense Fund Payment, Private Placement	0	0	53,040	Zentalis Pharmaceuticals Inc.	2,220	231
33,156	PrognomiQ Inc., Private Placement	1,006	29			511,456	581,924
86,851	Protagonist Therapeutics Inc.	3,578	4,819		Chemicals – 0.0%		
32,347	Prothena Corporation PLC	1,614	644	6,523	Ginkgo Bioworks Holdings Inc.	1,198	92
27,841	Regeneron Pharmaceuticals Inc.	25,825	28,507	331	Ginkgo Bioworks Holdings Inc., Earnout Shares 600, Private Placement	0	0
78,228	Relay Therapeutics Inc.	2,117	463	331	Ginkgo Bioworks Holdings Inc., Earnout Shares 700, Private Placement	0	0
147,149	Replimune Group Inc.	4,321	2,561	331	Ginkgo Bioworks Holdings Inc., Earnout Shares 800, Private Placement	0	0
140,693	Revolution Medicines Inc.	5,944	8,846			1,198	92
20,318	Revolution Medicines Inc., Warrants Dec 20, 2026	45	5		Corporate Bonds – 0.1%		
23,900	Rhythm Pharmaceuticals Inc.	1,640	1,923		Galvanize Therapeutics Inc. (USD)		
80,459	Ring Therapeutics Inc., Conv. Pref., Series B, Private Placement	930	532	902,200	Conv., Promissory Note, Private Placement 10.000% Feb 28, 2027	1,256	1,297
42,178	Ring Therapeutics Inc., Conv. Pref., Series C, Private Placement	533	279		Kardium Inc. (USD)		
89,227	Rocket Pharmaceuticals Inc.	2,799	1,612	451,100	Conv., Promissory Note, Private Placement 0.000% Dec 31, 2026	615	648
28,737	Sage Therapeutics Inc.	949	224			1,871	1,945
9,257	SalioGen Therapeutics Inc., Conv. Pref., Series B, Private Placement	1,247	194		Financial Services – 0.1%		
202,174	Sana Biotechnology Inc.	2,461	474		Helix Acquisition Corporation II, Class A, Private Placement	974	1,093
181,405	Scholar Rock Holding Corporation	5,628	11,270				
13,492	Scholar Rock Holding Corporation, Private Placement, Warrants Dec 31, 2025	0	707		Health Care Equipment & Supplies – 18.4%		
83,140	Scribe Therapeutics Inc., Conv. Pref., Series B, Private Placement	624	723	59,174	Becton Dickinson and Company	17,109	19,297
195,749	Seaport Therapeutics Inc., Conv. Pref., Series B, Private Placement	1,284	1,337	310,286	Boston Scientific Corporation	26,716	39,839
876,789	Sensorion SA	726	830	283,896	ChromaCode Inc., Conv. Pref., Series D-1, Private Placement	253	85
48,892	Sionna Therapeutics Inc., Conv. Pref., Series B, Private Placement	606	686	283,895	ChromaCode Inc., Conv. Pref., Series D-2, Private Placement	252	188
15,547	Sionna Therapeutics Inc., Conv. Pref., Series C, Private Placement	206	218	42,838	DexCom Inc.	4,064	4,789
29,867	Soleno Therapeutics Inc.	1,948	1,930	75,857	Edwards Lifesciences Corporation	7,968	8,072
61,692	SpringWorks Therapeutics Inc.	3,140	3,204	41,188	Hologic Inc.	2,929	4,268
32,484	Spyre Therapeutics Inc.	1,570	1,087	10,000	IDEXX Laboratories Inc.	6,829	5,943

No. of Shares or Units/ Par Value	Description	Cost	Fair Value	No. of Shares or Units/ Par Value	Description	Cost	Fair Value
122,902	Intuitive Surgical Inc.	\$ 23,156	\$ 92,212	26,200	Quest Diagnostics Inc.	\$ 5,416	\$ 5,682
525,506	Kardium Inc., Conv. Pref., Series D-5, Private Placement	676	642	52,527	Tenet Healthcare Corporation	6,860	9,531
918,382	Kardium Inc., Conv. Pref., Series D-6, Private Placement	1,185	1,122	52,719	The Cigna Group	16,047	20,926
17,471	Lantheus Holdings Inc.	1,819	2,247	133,863	UnitedHealth Group Inc.	46,928	97,338
14,700	Masimo Corporation	3,682	3,493			145,097	217,212
101,550	Novocure Limited	7,723	4,350		Health Care Technology – 0.1%		
46,339	Orchestra Biomed Holdings Inc.	617	266	2,230	DNA Script SAS, Conv. Pref., Series C, Private Placement	2,422	958
49,899	Penumbra Inc.	13,603	17,034	4,700	Veeva Systems Inc., Class A	1,692	1,420
39,345	PROCEPT BioRobotics Corporation	2,163	4,554			4,114	2,378
136,291	RefleXion Medical Inc., Conv. Pref., Series C, Private Placement	294	337		Insurance – 0.3%		
69,789	RefleXion Medical Inc., Conv. Pref., Series D, Private Placement	188	176	236,100	Oscar Health Inc., Class A	4,202	4,561
168,076	RefleXion Medical Inc., Conv. Pref., Series E, Private Placement	508	435		Life Sciences Tools & Services – 11.0%		
155,552	RefleXion Medical Inc., Conv. Pref., Series F, Private Placement	322	295	65,840	10X Genomics Inc., Class A	4,194	1,359
62,189	Saluda Medical Inc., Conv. Pref., Series D, Private Placement	993	951	37,803	Agilent Technologies Inc.	4,256	7,300
47,396	Saluda Medical Inc., Conv. Pref., Series E, Private Placement	516	659	46,747	Arbor Biotechnologies Inc., Conv. Pref., Series B, Private Placement	959	276
9,328	Saluda Medical Inc., Private Placement, Warrants Jan 20, 2027	0	26	27,153	Arbor Biotechnologies Inc., Conv. Pref., Series C, Private Placement	154	161
19,867	Sonova Holding AG	8,999	9,339	65,995	Bio-Techne Corporation	6,605	6,833
128,164	Stryker Corporation	32,634	66,332	24,130	Bruker Corporation	1,550	2,033
25,500	The Cooper Companies Inc.	3,754	3,370	177,253	Cellanome Inc., Conv. Pref., Series A, Private Placement	1,249	1,908
		168,952	290,321	320,179	Clear Labs Inc., Conv. Pref., Series C, Private Placement	1,351	1,456
	Health Care Providers & Services – 13.8%			31,768	Clear Labs Inc., Conv. Pref., Series D, Private Placement	141	142
125,400	Alignment Healthcare Inc.	2,033	2,028	52,180	Cleerly Inc., Conv. Pref., Series C, Private Placement	796	884
169,471	BrightSpring Health Services Inc.	3,180	4,149	178,959	Danaher Corporation	46,523	59,050
69,922	Capsule Corporation, Conv. Pref., Series 1-D, Private Placement	1,279	130	96,804	Freenome Holdings Inc., Conv. Pref., Series B, Private Placement	581	772
79,929	Capsule Corporation, Conv. Pref., Series E, Private Placement	314	148	62,914	Freenome Holdings Inc., Conv. Pref., Series C, Private Placement	552	502
30,254	Cardinal Health Inc.	4,443	5,143	46,462	Freenome Holdings Inc., Conv. Pref., Series D, Private Placement	445	372
14,526	Cencora Inc.	4,173	4,691	15,466	Freenome Holdings Inc., Conv. Pref., Series F, Private Placement	154	124
57,470	Centene Corporation	4,365	5,004	8,106	ICON PLC, ADR	2,904	2,444
21,741	Color Health Inc., Conv. Pref., Series D, Private Placement	1,042	553	118,869	Inscripta Inc., Conv. Pref., Series E, Private Placement	1,326	320
26,901	Color Health Inc., Conv. Pref., Series D-1, Private Placement	729	464	406	LUMICKS Technologies BV, Conv. Pref., Series D, Private Placement	911	541
3,876	Color Health Inc., Conv. Pref., Series E, Private Placement	480	220	146,343	Pacific Biosciences of California Inc.	2,604	385
56,751	Elevance Health Inc.	25,229	30,094	20,109	Repligen Corporation	4,470	4,161
6,400	Encompass Health Corporation	889	850	34,400	Revvity Inc.	5,350	5,519
3,917	GeneDx Holdings Corporation	1,357	433	13,856	Sartorius AG, Preference	4,964	4,426
17,442	GeneDx Holdings Corporation, Warrants Sep 24, 2027	77	4	8,838	SomaLogic Inc., Warrants Aug 31, 2026	28	0
27,286	HCA Healthcare Inc.	6,378	11,772	96,721	Thermo Fisher Scientific Inc.	45,742	72,328
218,299	Honor Technology Inc., Conv. Pref., Series D, Private Placement	693	537	6,813	Verily Life Sciences LLC, Series B, Private Placement	1,121	659
181,644	Honor Technology Inc., Conv. Pref., Series E, Private Placement	733	446			138,930	173,955
7,103	Humana Inc.	3,290	2,590				
5,240	McKesson Corporation	2,998	4,293				
24,346	Molina Healthcare Inc.	6,164	10,186				

No. of Shares or Units/ Par Value	Description	Cost	Fair Value
Pharmaceuticals – 19.0%			
547,851	Affinivax AFX3772 Milestone Event, Private Placement	\$ 334	\$ 583
928	Affinivax Expense Fund, Private Placement	1	1
547,851	Affinivax Next Gen Product Milestone Event, Private Placement	334	291
55,396	Alto Neuroscience Inc.	1,095	337
39,074	Arvinas Inc.	2,332	1,077
350,911	AstraZeneca PLC, ADR	24,876	33,049
733,645	Avalyn Pharma Inc., Conv. Pref., Series C-1, Private Placement	724	772
131,600	Chugai Pharmaceutical Company Limited	6,778	8,339
144,991	Eli Lilly & Company	49,591	160,898
31,473	EyePoint Pharmaceuticals Inc.	671	337
55,988	Insitro Inc., Conv. Pref., Series B, Private Placement	486	1,472
47,325	Insitro Inc., Conv. Pref., Series C, Private Placement	1,093	1,244
162,997	Kartos Therapeutics Inc., Conv. Pref., Series C, Private Placement	1,249	1,325
18,300	MBX Biosciences Inc.	398	485
60,252	MBX Biosciences Inc., Lockup Shares, Private Placement	1,034	1,596
279,998	Merck & Company Inc.	35,749	40,039
220,196	Metsera Inc., Conv. Pref., Series B, Private Placement	1,547	1,595
37,249	Novo Nordisk AS, ADR	4,936	4,606
30,000	Ocular Therapeutix Inc.	390	368
27,608	Pharvaris NV	849	761
39,017	Pliant Therapeutics Inc.	1,286	739
75,501	Rapport Therapeutics Inc.	1,667	1,925
99,813	Sail Biomedicines Inc., Conv. Pref., Series B, Private Placement	3,479	316
228,487	Sanofi SA, ADR	16,700	15,841
34,730	Septerna Inc.	869	1,143
44,441	Structure Therapeutics Inc., ADR	2,798	1,733
27,494	Tarsus Pharmaceuticals Inc.	1,546	2,188
102,200	Teva Pharmaceutical Industries Limited, ADR	3,134	3,238
177,461	Third Arc Bio Inc., Conv. Pref., Series A, Private Placement	511	537
23,726	Third Harmonic Bio Inc.	425	351
8,825	UCB SA	2,341	2,525
119,631	Verona Pharma PLC, ADR	3,856	7,986
158,103	WAVE Life Sciences Limited	1,886	2,811
		174,965	300,508
	Transaction Costs	(345)	
	TOTAL INVESTMENT		
	PORTFOLIO – 99.7%	\$ 1,151,414	\$ 1,573,989
	TOTAL PORTFOLIO		\$ 1,573,989

*Note: Percentages shown relate investments at
fair value to Net Assets as at the period end.*

Fund-Specific Notes to the Financial Statements

The Fund

(I) The Fund was inception on September 20, 1996 and its operations commenced on October 30, 1996.

(II) TDAM is the manager, portfolio adviser and trustee of the Fund. TDAM has retained T. Rowe Price Associates, Inc. as sub-adviser for the Fund in addition to TDAM.

(III) The presentation and functional currency of the Fund is the Canadian dollar.

(IV) The investment objective of the Fund is to seek to achieve long-term capital appreciation by investing primarily in equity securities of companies whose products or services relate to the health sciences industry. In seeking to achieve this objective, the Fund invests at least 65 percent of its total assets in common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. Stock selection is based on fundamental, bottom-up analysis seeking to identify high-quality companies and sound investment opportunities. The sub-adviser of the Fund primarily uses a growth approach to stock selection, with an emphasis on a value approach when stock valuations seem unusually high.

(V) O-Series was launched on March 30, 2023.

Management Fees and Administration Fees (%) (Note 6)

for the periods ended December 31, 2024 and 2023 (exclusive of GST and HST)

Series	Annual Rate	
	Management Fees*	Administration Fees
Investor Series	2.25	0.20
Advisor Series	2.25	0.20
F-Series	1.25	N/A
D-Series	1.25	0.20
O-Series	0.00	N/A

* Includes management fees paid by the Fund and the proportionate management fees, if any, of the Underlying Funds managed by TDAM held by the Fund. However, no management fees are payable by the Fund that, to a reasonable person, would duplicate a fee payable by the Underlying Funds for the same services.

Brokerage Commissions and Soft Dollars (in 000s) (Notes 3 and 6)

for the periods ended December 31, 2024 and 2023

	2024	2023
Total Brokerage Commissions	\$ 472	\$ 379
Commissions Paid to Related Parties	0	0
Soft Dollars	51	0

Tax Loss Carry Forwards (in 000s) (Note 7)

as at December 31, 2024

Capital Losses	\$	10,241
Non-Capital Losses (by year of expiry)		
2026	\$	1,869
2028		3,708
2029		3,132
2031		69
2042		9,422

Securities Lent (Note 3)

(I) SECURITIES LENDING INCOME

A reconciliation of the gross amount generated from the securities lending transactions to the securities lending income to the Fund for the periods ended December 31, 2024 and 2023 is as follows:

	Amount (in 000s)		Percentage of Total Amount (%)	
	2024	2023	2024	2023
Gross Securities Lending Income	\$ 243	\$ 355	100.0	100.0
Agent Fees – The Bank of New York Mellon	(54)	(68)	(22.1)	(19.2)
Securities Lending Income to the Fund before Tax Reclaims (Withholding Taxes)	189	287	77.9	80.8
Tax Reclaims (Withholding Taxes)	(9)	(59)	(3.8)	(16.6)
Net Securities Lending Income	\$ 180	\$ 228	74.1	64.2

(II) SECURITIES LENT AND COLLATERAL HELD (in 000s)

The table below summarizes the aggregate securities lent and related collateral held by the Fund as at December 31, 2024 and 2023.

	2024	2023
Fair Value of Securities Lent	\$ 86,424	\$ 59,917
Fair Value of Collateral Held	92,991	62,948

Collateral held is in the form of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments or corporations and is not included in the Statements of Financial Position.

Financial Risk Management (Notes 3, 4 and 8)

as at December 31, 2024 and 2023

(I) INTEREST RATE RISK

Not significant to the Fund.

(II) CURRENCY RISK

The following tables indicate the currencies (other than the Fund's functional currency) to which the Fund had exposure to as at December 31, 2024 and 2023, including the underlying principal amount of foreign exchange forward contracts, as applicable. The tables also illustrate the potential impact to the Fund's net assets if the Fund's functional currency had strengthened or weakened by 5 percent in relation to all exposure to other currencies, with all other variables held constant. In practice, the actual trading results may differ from these approximate sensitivity amounts and the differences could be material.

Currency (in 000s)	Financial Instruments*	Foreign Exchange Forward Contracts*	Total Exposure	Impact on Net Assets
Dec 31, 2024				
Danish Krone	\$ 0	\$ 0	\$ 0	\$ 0
Euro	8,740	0	8,740	437
Japanese Yen	8,339	0	8,339	417
Swiss Franc	9,338	0	9,338	467
United States Dollar	1,555,267	0	1,555,267	77,763
Total	\$ 1,581,684	\$ 0	\$ 1,581,684	\$ 79,084

As Percentage of Net Assets (%)

100.2 5.0

Currency (in 000s)	Financial Instruments*	Foreign Exchange Forward Contracts*	Total Exposure	Impact on Net Assets
Dec 31, 2023				
Danish Krone	\$ 3,265	\$ 0	\$ 3,265	\$ 163
Euro	11,054	0	11,054	553
Japanese Yen	4,508	0	4,508	225
Swiss Franc	3,133	0	3,133	157
United States Dollar	1,670,038	0	1,670,038	83,502
Total	\$ 1,691,998	\$ 0	\$ 1,691,998	\$ 84,600

As Percentage of Net Assets (%)

100.2 5.0

* Includes both monetary and non-monetary instruments, where applicable.

(III) OTHER PRICE RISK

The table below summarizes the impact of other price risk to the Fund. As at December 31, 2024 and 2023, had the benchmark of the Fund increased or decreased by 5 percent, with all other variables held constant, the net assets of the Fund would have increased or decreased by approximately:

	2024	2023
Benchmark	Weight (%)	
Lipper Health/Biotechnology Funds Index (C\$)	100.00	100.00
Impact on Net Assets (in 000s)	\$ 71,528	\$ 77,341
Impact on Net Assets (%)	4.5	4.6

In practice, the actual trading results may differ from the above estimated amounts and the differences could be material.

(IV) CREDIT RISK

Not significant to the Fund.

(V) FINANCIAL INSTRUMENTS BY THE LEVEL IN THE FAIR VALUE HIERARCHY

(in 000s)

The tables below illustrate the classification of the Fund's financial instruments within the fair value hierarchy as at December 31, 2024 and 2023.

	Level 1	Level 2	Level 3	Total
Dec 31, 2024				
Equities	\$ 1,473,958	\$ 26,225	\$ 69,555	\$ 1,569,738
Bonds	0	0	1,945	1,945
Warrants	9	2,271	26	2,306
	\$ 1,473,967	\$ 28,496	\$ 71,526	\$ 1,573,989

During the period, transfers between Level 1 and Level 2 were not significant.

	Level 1	Level 2	Level 3	Total
Dec 31, 2023				
Equities	\$ 1,572,300	\$ 21,842	\$ 68,795	\$ 1,662,937
Warrants	10	259	36	305
	\$ 1,572,310	\$ 22,101	\$ 68,831	\$ 1,663,242

During the period, transfers between Level 1 and Level 2 were not significant.

(VI) RECONCILIATION OF LEVEL 3 FAIR VALUE MEASUREMENTS (in 000s)

The tables below reconcile the Fund's Level 3 fair value measurements from January 1, 2024 to December 31, 2024 and January 1, 2023 to December 31, 2023.

	Equities	Bonds	Warrants
Balance at Jan 1, 2024	\$ 68,795	\$ 0	\$ 36
Purchases and Accretion of Interest	14,051	1,871	0
Sales, Paydowns and Maturity	(599)	0	0
Net Transfers In (Out)	(6,921)	0	0
Gains (Losses)			
Net Realized Gain (Loss) on Sale of Investments and Derivatives	47	0	0
Net Change in Unrealized Appreciation (Depreciation) of Investments and Derivatives	(5,818)	74	(10)
Balance at Dec 31, 2024	\$ 69,555	\$ 1,945	\$ 26
Total Change in Unrealized Appreciation (Depreciation) for Assets Held at Dec 31, 2024	\$ (5,806)	\$ 74	\$ (10)

	Equities	Warrants
Balance at Jan 1, 2023	\$ 77,153	\$ 0
Purchases and Accretion of Interest	6,333	0
Sales, Paydowns and Maturity	(1,764)	0
Net Transfers In (Out)	(362)	0
Gains (Losses)		
Net Realized Gain (Loss) on Sale of Investments and Derivatives	619	0
Net Change in Unrealized Appreciation (Depreciation) of Investments and Derivatives	(13,184)	36
Balance at Dec 31, 2023	\$ 68,795	\$ 36
Total Change in Unrealized Appreciation (Depreciation) for Assets Held at Dec 31, 2023	\$ (13,393)	\$ 36

As at December 31, 2024, if the value of the Level 3 investments were to increase or decrease by 10%, the value of the Fund would increase or decrease by \$7,153 (December 31, 2023: \$6,883).

Investment Portfolio Concentration (%) (Note 8)

The following tables summarize the Fund's investment portfolio concentration as at December 31, 2024 and 2023:

	2024
Biotechnology	36.9
Pharmaceuticals	19.0
Health Care Equipment & Supplies	18.4
Health Care Providers & Services	13.8
Life Sciences Tools & Services	11.0
Cash (Bank Overdraft)	0.4
Insurance	0.3
Health Care Technology	0.1
Corporate Bonds	0.1
Financial Services	0.1
Chemicals	0.0
Other Net Assets (Liabilities)	(0.1)
	100.0
	2023
Biotechnology	30.4
Health Care Providers & Services	19.8
Pharmaceuticals	17.7
Health Care Equipment & Supplies	15.9
Life Sciences Tools & Services	13.4
Cash (Bank Overdraft)	1.7
Health Care Technology	1.1
Insurance	0.1
Chemicals	0.0
Professional Services	0.0
Other Net Assets (Liabilities)	(0.1)
	100.0

Interest in Unconsolidated Structured Entities (Note 3)

as at December 31, 2024 and 2023

Not significant or applicable to the Fund.

Offsetting of Financial Assets and Liabilities (in 000s) (Note 3)

as at December 31, 2024 and 2023

Not significant or applicable to the Fund.

Notes to the Financial Statements

1. The Funds

The TD Mutual Fund Trusts and TD Managed Assets Program Portfolios (collectively, the "Funds" and individually, the "Fund") are open-end mutual funds established under the laws of Ontario and governed by their respective Declarations of Trust or Trust Indenture, as amended from time to time.

TD Asset Management Inc. ("TDAM") is the manager, portfolio adviser and trustee of the Funds. TDAM, TD Investment Services Inc. ("TDIS"), TD Waterhouse Canada Inc. ("TDWCI") and Epoch Investment Partners, Inc. ("Epoch") are wholly-owned subsidiaries of The Toronto-Dominion Bank. The registered address of the Funds is P.O. Box 100, 66 Wellington Street West, TD Bank Tower, Toronto-Dominion Centre, Toronto, Ontario, M5K 1G8.

The financial year-end for the Funds is December 31. The Statements of Financial Position are presented as at December 31, 2024 and 2023, as applicable. The Statements of Comprehensive Income, Statements of Changes in Net Assets Attributable to Holders of Redeemable Units and Statements of Cash Flows are presented for the twelve-month periods ended December 31, 2024 and 2023, as applicable. Where a Fund or series of a Fund was established during either period, the information for that Fund or series is provided from the inception date, as disclosed in the Fund-Specific Notes to the Financial Statements ("Fund-Specific Notes"), to the applicable period end date and a comparative statement has only been presented for any period for which that Fund was in existence as at the reporting date.

These financial statements were authorized for issue by TDAM on March 14, 2025.

2. Basis of Presentation

These financial statements have been prepared in accordance with *International Financial Reporting Standards as issued by the International Accounting Standards Board* ("IFRS"). These financial statements have been prepared on a going concern basis using the historical cost convention, as modified by the revaluation of financial assets and financial liabilities (including derivative financial instruments) at fair value through profit or loss ("FVTPL").

3. Summary of Material Accounting Policy Information

Financial Instruments

Financial instruments include financial assets and financial liabilities, such as investments, derivatives, cash, and other receivables and payables. Derivatives that are reflected in the Statements of Financial Position as Derivative Assets (Liabilities) include rights, warrants, forwards, options, futures and swap contracts, where applicable, and are financial contracts between two or more parties, and whose value is derived from the performance of an underlying asset or group of assets. Underlying assets include stocks, bonds, currencies, commodities, interest rates and market indices. The Funds classify and measure financial instruments in accordance with IFRS 9, "*Financial Instruments*". Upon initial recognition, financial instruments are measured at FVTPL. All financial assets and liabilities are recognized in the Statements of Financial Position when a Fund becomes a party to the contractual requirements of the instrument. Financial instruments are derecognized when the right to receive cash flows from the instrument has expired

or a Fund has transferred substantially all risks and rewards of ownership. As such, investment purchase and sale transactions are recorded as of the trade date.

The Funds' financial assets and financial liabilities, other than receivables and payables, are subsequently measured at FVTPL with changes in fair value recognized in the Statements of Comprehensive Income. Other receivables and payables are subsequently measured at amortized cost.

The Funds have determined that they meet the definition of an 'investment entity' within IFRS 10, "*Consolidated Financial Statements*" and as a result, the Funds measure subsidiaries, if any, at FVTPL. An investment entity is an entity that: obtains funds from one or more investors for the purpose of providing them with investment management services; commits to its investors that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and measures and evaluates the performance of substantially all of its investments on a fair value basis. The Funds' investments may also include associates and joint ventures which are measured at FVTPL.

The Funds' outstanding redeemable units' entitlements include a contractual obligation to distribute any net income and net realized capital gains in cash (at the request of the unitholder) and therefore the ongoing redemption feature is not the Funds' only contractual obligation. Consequently, the Funds' Net Assets Attributable to Holders of Redeemable Units are classified as financial liabilities in accordance with the requirements of IAS 32, "*Financial Instruments: Presentation*". The Funds' obligations for Net Assets Attributable to Holders of Redeemable Units are presented at the redemption amount.

The accounting policies for measuring the fair value of the Funds' investments and derivatives are substantially similar to those used in measuring the Funds' net asset value ("NAV") for transactions with unitholders. The NAV is the value of the total assets of a fund less the value of its total liabilities determined, on each valuation day, in accordance with Part 14 of National Instrument 81-106, "*Investment Fund Continuous Disclosure*", for the purpose of processing unitholder transactions. Net Assets Attributable to Holders of Redeemable Units, also referred to as Net Assets, refers to net assets calculated in accordance with IFRS. As at all dates presented, there were no differences between the Funds' NAV per series unit and Net Assets per series unit.

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and marketable securities) is based on quoted market prices at the close of trading on the reporting date. The Funds use the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, TDAM determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. For equities traded in active markets outside of North America or South America, fair value pricing, instead of last traded market price, will be used in circumstances to avoid stale prices and apply fair value factors that take into account, such as, among other things, any significant events occurring after the close of a foreign market.

Notes to the Financial Statements

The fair value of financial assets and liabilities not traded in an active market, including over-the-counter derivatives, is determined using valuation techniques. The Funds use a variety of methods and make assumptions that are based on market conditions existing at each reporting date. Valuation techniques include the use of comparable recent arm's length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, option pricing models and other techniques commonly used by market participants and which attempt to make the maximum use of observable inputs.

The valuation methodology for specific types of investments held by the Funds is summarized below.

- (a) Securities not listed on any recognized public securities exchange are valued based on available quotations from recognized dealers in such securities, where readily available. If securities have no available broker-dealer bid/ask quotes, TDAM uses different valuation techniques and models as described above with inputs that TDAM believes are relevant in the circumstances to price the securities. Debt instruments are valued based on mid prices, where readily available.
- (b) Short-term debt instruments, repurchase and reverse repurchase agreements are valued based on quotations received from recognized investment dealers.
- (c) The Funds may use foreign exchange forward contracts to hedge against or profit from fluctuations in foreign exchange rates. These contracts are valued on each valuation day based on the difference between the contract rates and the current forward rates at the measurement date applied to the contracts' notional amount. The net change in unrealized appreciation or depreciation and the net realized gain or loss from closing out contracts are reflected in the Statements of Comprehensive Income as part of Net Gain (Loss) on Investments and Derivatives.
- (d) Options contracts that are traded in exchange markets are valued at their mid prices on each valuation day. The premium received or paid on options written or purchased is included in the cost of the options. Any difference between the current value of the contract and the value of the contract originated is recognized as Net Change in Unrealized Appreciation (Depreciation). When options are closed or exercised, the difference between the premium and the amount paid or received, or the full amount of the premium if the option expires worthless, is reflected in the Statements of Comprehensive Income as Net Realized Gain (Loss). The cost of a security purchased will be reduced by the premium received on options when a written put option is exercised or increased by the amount paid on options when a purchased call option is exercised.
- (e) The Funds may enter into standardized, exchange-traded futures contracts to purchase or sell a financial instrument at a contracted price on a specified future date. Any difference between the value at the close of business on the current valuation day and that of the previous valuation day is settled in cash daily and recorded in the Statements of Comprehensive Income as Derivatives Income (Loss). Any cash deposits or borrowings on margin are reflected in the Statements of Financial Position as Margin Deposit (Payable) on Derivatives. Short-term debt instruments as indicated in the Schedule of Investment Portfolio have been segregated and are held as margin against the futures contracts entered into by the Funds, as applicable.
- (f) Certain Funds may enter into total return swap ("TRS") agreements with one or more counterparties to gain exposure to the swap reference assets. Under each swap, the Funds pay the counterparties a floating amount based on the prevailing short-term market interest rates computed upon an agreed notional amount. Additionally, the Funds also pay an amount based upon a decline in value, if any, of a notional investment in a notional number of units, the value of which will equal the value of the swap reference assets. In return, the counterparties pay the Funds an amount based upon any increase in value of the swap reference assets.

Floating amounts paid to the counterparties are accrued daily and recorded as Derivative Income (Loss) in the Statements of Comprehensive Income. Changes in the fair value of the TRS agreements outstanding at the reporting date are disclosed in the Statements of Comprehensive Income as Net Change in Unrealized Appreciation (Depreciation). TRS agreements are valued at the amount that the Funds would receive or pay to terminate the agreements. When TRS agreements mature or are closed out, the net realized gain or loss is reflected in the Statements of Comprehensive Income as Net Realized Gain (Loss).
- (g) Certain Funds may enter into dividend swap agreements with one or more counterparties to gain exposure to the dividends of the swap reference common shares. Under each swap, the Funds pay the counterparties a fixed amount based on fixed strike price times the number of swap reference common shares. In return, the counterparties pay the Funds a floating amount based on the dividends of the swap reference common shares.

Changes in the fair value of the dividend swap agreements outstanding at the reporting date are disclosed in the Statements of Comprehensive Income as Net Change in Unrealized Appreciation (Depreciation). Prices used to value the dividend swap agreements are obtained directly from the data vendor. When dividend swap agreements mature or are closed out, the net realized gain or loss is reflected in the Statements of Comprehensive Income as Net Realized Gain (Loss).
- (h) Certain Funds may enter into credit default swap ("CDS") agreements to gain exposure to debt instruments without investing in them directly. A CDS agreement is a bilateral over-the-counter derivative contract between a protection buyer and a protection seller that exchange the credit risk of a specific issuer (reference entity). The protection buyer pays a periodic premium, often quarterly, to the protection seller to assume the credit risk associated with a particular credit event. Credit events include bankruptcy, a material default and debt restructuring for a specified reference asset. If a credit event occurs, the CDS agreements may be settled by either the physical delivery of the referenced asset for proceeds equal to par value or a cash payment equal to the loss amount. If there is no credit default event, no contingent amount is payable.

During the reporting periods, certain Funds have entered into CDS agreements as protection seller. Any upfront payment made or received by these funds at the initiation of a CDS agreement is included in the CDS agreement's fair value. Quarterly premiums received from the counterparty are accrued daily and recorded as Derivative Income (Loss) in the Statements of Comprehensive Income. Changes in the fair value of the CDS agreements outstanding at the reporting date are disclosed in the Statements of Comprehensive Income as Net Change in Unrealized Appreciation (Depreciation).

Notes to the Financial Statements

Prices used to value the CDS are obtained directly from the data vendor or broker. When CDS agreements expire or are closed out, the net realized gain or loss is reflected in the Statements of Comprehensive Income as Net Realized Gain (Loss).

The exposure to CDS is limited to the notional amount of the contract less any applicable recoverable amount, calculated by the product of the notional amount and the recovery rate of the respective reference entity.

- (i) The exchange-traded funds ("ETFs") that are not managed by TDAM are valued based on quoted market prices at the close of trading on the reporting date.
- (j) Investments in underlying mutual funds, TDAM managed ETFs and other underlying funds are generally valued at the NAV per series unit of the investment funds as reported by the investment funds' managers.
- (k) Certain Funds may enter into commitments to purchase when-issued securities through private investment in public equity (PIPE) transactions with special purpose acquisition companies (SPACs). A SPAC is a publicly traded company that raises investment capital via an initial public offering for the purpose of acquiring the equity securities of one or more existing companies via merger, business combination, acquisition, or other similar transactions within a designated time frame. A PIPE typically involves the purchase of securities directly from a publicly traded company in a private placement transaction. Securities purchased through the PIPE transaction will be restricted from trading and considered illiquid until a resale registration statement for the securities is filed and declared effective. The commitments are contingent upon the SPACs acquiring the securities of target companies. Unrealized appreciation or depreciation on these commitments as at the reporting period ends is separately presented in Statements of Financial Position as Unrealized Appreciation (Depreciation) on Unfunded Commitments, and any change in fair value during the reporting periods is included in the Net change in Unrealized Appreciation (Depreciation) on Unfunded Commitments in the Statements of Comprehensive Income.

Fair Value Hierarchy

The Funds classify their investments into fair value measurements within a hierarchy that prioritizes the inputs to fair value measurement. The fair value hierarchy has the following three levels:

- Level 1 Quoted (unadjusted) prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly (that is, as prices) or indirectly (that is, derived from prices); and
- Level 3 Inputs that are not based on observable market data (that is, unobservable inputs).

All fair value measurements are recurring. The carrying values of Cash, Margin Deposit on Derivatives, Subscriptions Receivable, Interest and Dividends Receivables, Receivable for Investments Sold, Bank Overdraft, Margin Payable on Derivatives, Payable for Investments Purchased, Redemptions Payable, Distributions Payable, Accrued Liabilities and the redemption value of Funds' obligation for Net Assets Attributable to Holders of Redeemable Units approximate their fair values due to their short-term nature.

Fair values are classified as Level 1 when the related security or derivative is actively traded and a quoted price is available. If an instrument classified as Level 1 subsequently ceases to be actively traded, it is transferred out of Level 1. In such cases, instruments are reclassified into Level 2, unless the measurement of their fair value requires the use of significant unobservable inputs, in which case they are classified as Level 3. The Funds' policy is to recognize transfers into and out of the fair value hierarchy levels at the end of the reporting period.

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

The classification within the hierarchy is based on the lowest level input that is significant to the fair value measurement. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgment, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgment. Observable data is considered to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

TDAM has a Valuation Committee which oversees the performance of the fair value measurements included in the financial statements of the Funds, including any Level 3 measurements. TDAM utilizes a variety of methods (as listed in the Fair Value Measurement section) in determining the fair value of securities classified as Level 3. The committee also meets quarterly to perform reviews of the valuations of investments held by the Funds.

The classification of the Funds' financial instruments within the fair value hierarchy as at December 31, 2024 and 2023, and any transfers between levels during the reporting periods as a result of changes in the lowest level input that is significant to the fair value measurement are disclosed in the Fund-Specific Notes, where applicable.

Interest in Unconsolidated Structured Entities

A structured entity is an entity that has been designed so that voting or similar rights are not the dominant factor in deciding who controls the entity, such as when any voting rights relate to administrative tasks only and the relevant activities are directed by means of contractual arrangements. TDAM has determined that all of the underlying investment funds ("Underlying Funds") in which the Funds invest are unconsolidated structured entities. Underlying Funds include mutual funds, ETFs and other funds that meet the definition of an investment entity within IFRS 10. In making this determination, TDAM evaluated the fact that decision making about Underlying Funds' activities is generally not governed by voting or similar rights held by the Funds and other investors in any Underlying Funds.

The Funds may invest in Underlying Funds whose investment objectives range from seeking to achieve short- to long-term income and/or capital growth potential. The Funds' interests in these securities as at December 31, 2024 and 2023 are included at their fair value in the Statements of Financial Position, which represent the Funds' exposure in these Underlying Funds. The Funds do not provide and have not

Notes to the Financial Statements

committed to provide any additional significant financial or other support to the Underlying Funds. The change in fair value of each of the Underlying Funds during the reporting periods is included in Net Change in Unrealized Appreciation (Depreciation) in the Statements of Comprehensive Income as part of Net Gain (Loss) on Investments and Derivatives. Additional information on the Funds' interest in Underlying Funds, where applicable, is provided in the Schedule of Investment Portfolio and Fund-Specific Notes.

Certain Funds may also invest in mortgage-related and/or other asset-backed securities that directly or indirectly represent a participation in, or are secured by and payable from, mortgage loans on real property. Mortgage-related securities are created from pools of residential or commercial mortgage loans, including mortgage loans made by savings and loan institutions, mortgage bankers, commercial banks and others. The debt and equity securities issued by these issuers may include tranches with varying levels of subordination. The Funds may invest in senior notes that have a first lien on assets and have minimum exposure to junior or subordinate tranches. These securities may provide a monthly payment which consists of both interest and principal payments. Other asset-backed securities are created from many types of assets, including auto loans, credit card receivables, home equity loans, and student loans.

As at December 31, 2024 and 2023, the fair value of mortgage-related and other asset-backed securities of these funds, where applicable, is disclosed as Investments in the Statements of Financial Position. The fair value represents the maximum exposure to losses at those dates. The change in fair value of mortgage-related and other asset-backed securities during the reporting periods is included in Net Change in Unrealized Appreciation (Depreciation) in the Statements of Comprehensive Income as part of Net Gain (Loss) on Investments and Derivatives.

Translation of Foreign Currencies

A Fund's functional currency, as disclosed in the Fund-Specific Notes, represents the currency that TDAM views to most faithfully represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration how units are issued or redeemed and how returns are measured. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates that transactions occur. Assets and liabilities denominated in a foreign currency are translated into the functional currency using the exchange rate prevailing at the measurement date.

Realized foreign exchange gains and losses on the sale of investments and derivatives are included in Net Realized Gain (Loss). Unrealized foreign exchange gains and losses on investments and derivatives are included in Net Change in Unrealized Appreciation (Depreciation). Realized and unrealized foreign exchange gains and losses relating to income, cash, other assets and liabilities are presented as Foreign Exchange Gain (Loss) on Cash and Other Net Assets in the Statements of Comprehensive Income.

Offsetting of Financial Assets and Liabilities

Financial assets and liabilities are offset and the net amount reported in the Statements of Financial Position where the Funds have a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. In the normal course of business, the Funds may enter into various master netting agreements or other similar arrangements that do not meet the criteria for offsetting in the Statements of

Financial Position but still allow for the related amounts to be set-off in certain circumstances, such as bankruptcy or the termination of the contracts. Offsetting information, where applicable, is presented in the Fund-Specific Notes.

Reverse Repurchase Agreements

Certain Funds may enter into reverse repurchase transactions. In a reverse repurchase transaction, a fund buys a security at one price from a third party and agrees to sell the same security back to the same party at a specified price on an agreed future date and the difference is reflected as Income from Reverse Repurchase Agreements in the Statements of Comprehensive Income.

The risk with these types of transactions is that the other party may default under the agreement or go bankrupt. These risks are reduced by requiring the other party to provide collateral to these funds. The value of the collateral must be at least 102 percent of the market value of the security and the collateral is marked to market on each business day. The type of securities received and related collateral held by these funds, where applicable, are listed in the Schedule of Investment Portfolio.

Cash/Bank Overdraft

Cash is comprised of deposits with financial institutions. Bank overdrafts are included under Current Liabilities in the Statements of Financial Position.

Margin Deposit (Payable) on Derivatives

Margin accounts represent margin deposits or payable in respect of derivatives entered into by the Funds.

Receivable for Investments Sold/Payable for Investments Purchased

Receivable for Investments Sold and Payable for Investments Purchased represent trades that have been contracted for but not yet settled or delivered on the Statements of Financial Position dates.

Valuation of Series Units

TDAM generally calculates the NAV for each series of the Funds as at 4 p.m. Eastern Time on each day that the Toronto Stock Exchange is open for trading. However, in some unforeseen circumstances, the series NAV per unit may be calculated at another time.

The NAV is calculated, for processing subscription, switch, conversion or redemption orders of series units, for each series of units of the Funds by taking the series' proportionate share of the individual Fund's common assets less that series' proportionate share of its common liabilities and deducting from this amount all liabilities that relate solely to that specific series.

The Net Assets Attributable to Holders of Redeemable Units – Per Series Unit is determined by dividing the total Net Assets Attributable to Holders of Redeemable Units of each series of the Funds by the total number of units outstanding of that series as at the reporting date.

Income Recognition

Interest for Distribution Purposes as shown in the Statements of Comprehensive Income consists of interest income from cash and the coupon interest on debt instruments accounted for on an accrual basis. Interest receivable is included in Interest and Dividends Receivables in the Statements of Financial Position based on the debt instruments' stated rates of interest. The Funds do not amortize premiums paid or discounts received on the purchase of debt securities except for zero coupon bonds which are amortized.

Notes to the Financial Statements

Dividend income from equities and distributions from ETFs is recognized on ex-dividend dates and distributions from Underlying Funds other than ETFs are recognized on ex-distribution dates. Distributions received from ETFs are periodically allocated to interest income, dividend income, capital gains and return of capital based on the nature of the underlying components. The allocations are calculated based on the best information available and actual allocations could be different.

Certain Funds may engage in securities lending pursuant to the terms of an agreement which includes restrictions as set out in Canadian securities legislation. The income earned from securities lending, where applicable, is included in the Statements of Comprehensive Income as it is earned. The fair value of the securities loaned and fair value of the collateral held are determined daily. The details of securities lending income, aggregate values of securities on loan and related collateral held are provided in the Fund-Specific Notes, where applicable.

Investment Transactions and Transaction Costs

For the purposes of calculating realized and unrealized gains and losses from investment transactions, the cost of each investment security is determined on an average cost basis, excluding transaction costs.

Transaction costs, such as brokerage commissions, incurred by the Funds in the purchase and sale of investments at fair value are recognized in the Statements of Comprehensive Income in the period incurred. No transaction costs are incurred when the Funds invest in Underlying Funds other than ETFs; however, the 'Underlying Funds' investments may be subject to transaction costs.

Allocation of Income and Expenses, Realized and Unrealized Gains (Losses)

Expenses (excluding interest charges and portfolio transaction costs) are accrued daily, separately for each series. Interest charges and portfolio transaction costs along with income, gains and losses, are allocated to each series based on their respective Net Assets Attributable to Holders of Redeemable Units of the Fund.

Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Per Series Unit

The Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Per Series Unit is calculated by dividing the Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units of each series by the weighted average units outstanding of that series for the reporting period, except when a series was established during the reporting period, in which case the Weighted Average Units Outstanding is calculated from the date of commencement of operation of that series.

New standards and amendments not yet effective

A number of new standards and amendments to standards are not yet effective as of December 31, 2024 and have not been applied in preparing these financial statements.

i) *Classification and Measurement of Financial Instruments* (Amendments to IFRS 9 and IFRS 7)

In May 2024, the IASB issued amendments to IFRS 9 and IFRS 7. Among other amendments, IASB clarified that a financial liability is derecognized on the 'settlement date' and introduced an accounting policy choice to derecognize financial liabilities settled using an electronic payment system before the settlement date. These amendments are effective for annual periods beginning on or after January 1, 2026, with early adoption permitted.

ii) *IFRS 18 Presentation and Disclosure in Financial Statements*

In April 2024, the IASB issued IFRS 18, which replaces IAS 1 *Presentation of Financial Statements*. It introduces several new requirements that are expected to impact the presentation and disclosure of the financial statements. These include:

- The requirement to classify all income and expense into specified categories and provide specified totals and subtotals in the statement of profit or loss.
- Enhanced guidance on the aggregation, location and labeling of items across the financial statements and the notes to the financial statements.
- Required disclosures about management-defined performance measures.

IFRS 18 is effective for annual periods beginning on or after January 1, 2027, with early adoption permitted.

The Funds are currently assessing the effect of the above standard and amendments. No other new standards and amendments are expected to have a material effect on the financial statements of the Funds.

4. Critical Accounting Estimates and Judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Funds have made in preparing the financial statements:

Fair Value Measurement of Derivatives and Securities Not Quoted in an Active Market

The Funds may hold financial instruments that are not quoted in active markets, including derivatives. As described in Note 3, the use of valuation techniques for financial instruments and derivatives that are not quoted in an active market requires TDAM to make assumptions that are based on market conditions existing as at the reporting date of the financial statements. Changes in assumptions about these factors could affect the reported fair values of financial instruments. Refer to the Fund-Specific Notes for further information about the fair value measurement of the Funds' financial instruments, where applicable.

Classification and Measurement of Investments

In classifying and measuring financial instruments held by the Funds, TDAM has assessed the Funds' business model for managing their respective portfolios of investments and evaluating the performance on a fair value basis, and concluded that these financial assets and liabilities should be measured at FVTPL in accordance with IFRS 9.

Investment Entity

In determining whether a Fund meets the definition of an investment entity, TDAM may be required to make significant judgments about whether a Fund has the typical characteristics of an investment entity. Each Fund may hold only one investment, an underlying fund (or have only one investor or have investors that are its related parties); however, consistent with the investment entity definition, each Fund primarily obtains funds from one or more investors for the purpose of providing investment management services, commits to its investors that the business purpose is to invest the funds solely for returns from capital appreciation, investment income or both, and measures and evaluates the performance of its investments on a fair value basis.

5. Redeemable Units

Each Fund is authorized to issue an unlimited number of units of multiple series that rank equally and are available for sale under its simplified prospectus. In addition, each of the TD Mutual Fund Trusts is also authorized to issue an unlimited number of units of multiple series to be sold under a confidential offering memorandum. The various series that may be offered by the Funds are as described below.

Investor Series:	Offered on a no-load basis to investors.
H5 Series and H8 Series:	Offered on a no-load basis to investors who wish to receive a regular monthly cash flow from the Funds. Monthly distributions may consist of net income, net realized capital gains and/or a return of capital.
Premium Series:	Offered on a no-load basis to large investors and others who make the required minimum investment, as determined by TDAM from time to time.
K-Series and K5 Series:	Offered on a no-load basis to large investors and others who make the required minimum investment, as determined by TDAM from time to time, and who wish to receive a regular monthly cash flow from the Funds. Monthly distributions may consist of net income, net realized capital gains, and/or a return of capital.
e-Series:	Offered on a no-load basis to investors who want to complete their transactions electronically, including through TD Direct Investing, a division of TDWCI, or other discount brokers.
D-Series:	Offered on a no-load basis to investors who want to complete their transactions through TD Direct Investing, a division of TDWCI, or other discount brokers.
Advisor Series:	Offered on a front-end load basis to investors who seek investment advice.
T5 Series and T8 Series:	Offered on a front-end load basis to investors who seek investment advice and wish to receive a regular monthly cash flow from the Funds. Monthly distributions may consist of net income, net realized capital gains and/or a return of capital.
F-Series:	Offered to investors, through fee-based financial advisors or dealer-sponsored "wrap accounts", and others who pay an annual fee to their dealer instead of transactional sales charges.
FT5 Series and FT8 Series:	Offered to investors, through fee-based financial advisors or dealer-sponsored "wrap accounts", who wish to receive a regular monthly cash flow from the Funds. Monthly distributions may consist of net income, net realized capital gains, and/or a return of capital. These series may also be offered to other investors who pay an annual fee to their dealer instead of transactional sales charges.
Premium F-Series:	Offered to large investors, through fee-based financial advisors or dealer-sponsored "wrap accounts", and others who pay an annual fee to their dealer instead of transactional sales charges. For this series, investors must make the required minimum investment, as determined by TDAM from time to time.

W-Series:	Offered to investors, through certain wealth management businesses of The Toronto-Dominion Bank Group, including certain divisions of TDWCI, or other dealers authorized by TDAM, who pay an annual fee to their dealer instead of transactional sales charges.
WT5 Series and WT8 Series:	Offered to investors who wish to receive a regular monthly cash flow from the Funds, through certain wealth management businesses of The Toronto-Dominion Bank Group, including certain divisions of TDWCI, or other dealers authorized by TDAM, who pay an annual fee to their dealer instead of transactional sales charges. Monthly distributions may consist of net income, net realized capital gains, and/or a return of capital.
Private Series and Private-EM Series:	Offered on a no-load basis to large investors who make the required minimum investment as determined by TDAM, and have entered into a Private Series agreement with TDAM.
Institutional Series:	Offered on a no-load basis to large investors, such as group savings plans and others who make the required minimum investment, as determined by TDAM from time to time.
O-Series:	Offered on a no-load basis to large investors, such as institutions and mutual funds, who make the required minimum investment as determined by TDAM, and have entered into an O-Series agreement with TDAM.
G-Series:	Offered on a no-load basis to large investors, such as institutions, group savings or pension plans and mutual funds, who make the required minimum investment as determined by TDAM and have entered into a G-Series agreement with TDAM.

Each individual series of units is sold under different purchase options and may have higher or lower management fees based on their specific attributes, as summarized above, reflecting the extent of the investment advice and/or services provided.

Units of the Funds are redeemable at the option of the unitholder in accordance with their respective provisions of the Declarations of Trust or Trust Indenture. Units of these funds are issued or redeemed on a daily basis at the NAV per series unit next determined after the subscription, switch, conversion order or redemption request, respectively, is received by TDAM. Subscriptions and redemptions include units converted from one series to another series within a Fund in the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units. However, conversions between series within a Fund are excluded from Proceeds from Issuance of Redeemable Units and Amounts Paid on Redemption of Redeemable Units in the Statements of Cash Flows.

6. Related Party Transactions

Capital

TDAM, affiliates of TDAM, and/or other investment funds managed by TDAM may invest in units of the Funds from time to time. The investment made by related parties is disclosed in the Fund-Specific Notes if significant.

Notes to the Financial Statements

Custodian

The Toronto-Dominion Bank is the custodian of the TD Balanced Index Fund which holds assets (including cash and investments) of this fund. The Toronto-Dominion Bank is the sub-custodian of the Funds (except for TD Balanced Index Fund) which holds a portion of the assets (including cash and investments) of the Funds. The Toronto-Dominion Bank may earn fees and spreads in connections with banking (including deposit taking) services provided to the Funds.

The Funds' cash held with The Toronto-Dominion Bank, which acts as a sub-custodian for the Funds at the end of the reporting period, where significant, is also disclosed in the Fund-Specific Notes.

Management Fees

(a) TD Mutual Fund Trusts

In consideration for the provision of management, distribution, and portfolio management services and oversight of any portfolio sub-advisory services provided to the TD Mutual Fund Trusts, TDAM receives an annual management fee in respect of certain series of these funds. The management fee is calculated and accrued on a daily basis for each applicable series based on the NAV of that series and paid monthly to TDAM.

No management fees are charged with respect to Private Series, O-Series and G-Series units. Instead, unitholders in Private Series, O-Series and G-Series units may be charged a fee directly by TDAM.

(b) TD Managed Assets Program Portfolios

In consideration for the provision of management, distribution and portfolio management services to the TD Managed Assets Program Portfolios, certain series of these funds pay TDAM an annual management fee. The management fee is calculated and accrued on a daily basis for each series based on the NAV of that series and paid monthly to TDAM.

No management fees are charged with respect to G-Series units. Instead, unitholders in G-Series units may be charged a fee directly by TDAM.

Where the TD Mutual Fund Trusts and TD Managed Assets Program Portfolios invest in Underlying Funds, there are fees and expenses payable by the Underlying Funds in addition to those paid by the Funds. However, no management fees are payable by Funds that invest in Underlying Funds that, to a reasonable person, would duplicate a fee payable by the Underlying Funds for the same services. Detailed information on the management fees of the Funds is provided in the Fund-Specific Notes.

Administration Fees

(a) TD Mutual Fund Trusts

In consideration for paying certain operating expenses, TDAM is paid an annual administration fee with respect to Investor Series, H5 Series, H8 Series, Premium Series, K-Series, D-Series, Advisor Series, T5 Series, T8 Series, Private Series and G-Series of certain TD Mutual Fund Trusts. Detailed information on the administration fee is provided in the "Management Fees and Administration Fees" section of the Fund-Specific Notes and any series with no administration fee is noted with "N/A" in this section of the Fund-Specific Notes.

Except for G-Series, the administration fee includes all operating expenses, other than costs such as all taxes, borrowing, IRC, compliance with any new governmental and regulatory requirements, and new types of costs or expenses. For G-Series, the administration fee includes all operating expenses. The administration fee is calculated and accrued on a daily basis for each applicable series based on the NAV of that series and paid monthly to TDAM.

(b) TD Managed Assets Program Portfolios

Except for the G-Series of these funds and TD Managed ETF Portfolios, no administration fee is charged to the TD Managed Assets Program Portfolios. For the G-Series of these funds, in consideration for paying all operating expenses, TDAM is paid an annual administration fee. For the TD Managed ETF Portfolios, in consideration for paying certain operating expenses, TDAM is paid an annual administration fee with respect to D-Series and F-Series of the TD Managed ETF Portfolios. The administration fee includes all operating expenses, other than costs such as all taxes, borrowing, IRC, compliance with any new governmental and regulatory requirements, and new types of costs or expenses.

The administration fee is calculated and accrued on a daily basis for each applicable series based on the NAV of that series and paid monthly to TDAM. Detailed information on the administration fee is provided in the Fund-Specific Notes.

Operating Expenses

Fund's Independent Review Committee ("IRC")

TDAM is responsible for management of the Funds' investment portfolios, including the making of decisions relating to the investment of the Funds' assets.

TDAM has established an IRC in respect of the Funds. The IRC acts as an impartial and independent committee to review and provide recommendations or, if appropriate, approvals respecting any conflict of interest matters referred to it. The IRC prepares, at least annually, a report of its activities for unitholders of the Funds.

Investments in securities of The Toronto-Dominion Bank, interests in Underlying Funds managed by TDAM, or investments in any affiliates that were held by the Funds at the end of the reporting period, where significant, are disclosed in the Schedule of Investment Portfolio and/or the Fund-Specific Notes.

The compensation and relevant expenses of IRC members are allocated proportionately among the investment funds managed by TDAM and disclosed in the Statements of Comprehensive Income as Independent Review Committee Fees.

(a) TD Mutual Fund Trusts

TDAM pays all of the operating expenses with respect to O-Series and G-Series units of the TD Mutual Fund Trusts.

The following Private Series, Private-EM Series and Advisor Series of the TD Mutual Fund Trusts bear their respective pro rata share of the operating expenses which are common to the operation of all series of these funds as well as those expenses which are attributable solely to that series (which may be payable to TDAM or its affiliates), including IRC costs, recordkeeping and communication costs, custodial, legal, audit and filing fees, bank charges, borrowing costs, all taxes, costs relating to compliance with any new governmental and regulatory requirements, and new types of costs or expenses.

Private Series: TD U.S. Money Market Fund, TD Short Term Bond Fund, TD Canadian Bond Fund, TD Canadian Corporate Bond Fund, TD U.S. Corporate Bond Fund, TD North American Sustainability Bond Fund, TD Global Income Fund, TD Global Core Plus Bond Fund, TD Global Unconstrained Bond Fund, TD High Yield Bond Fund, TD Global Conservative Opportunities Fund, TD Global Balanced Opportunities Fund, TD Canadian Diversified Yield Fund, TD Canadian Low Volatility Fund, TD Canadian Blue Chip Dividend Fund, TD Canadian Large-Cap Equity Fund, TD Canadian Equity Fund, TD U.S. Low Volatility Fund, TD North American Sustainability Equity Fund, TD U.S. Dividend Growth Fund, TD U.S. Shareholder Yield Fund, TD U.S. Equity Focused Fund, TD U.S. Equity Focused Currency Neutral Fund, TD U.S. Large-Cap Value Fund, TD U.S. Disciplined Equity Alpha Fund™, TD Global Low Volatility Fund, TD Global Shareholder Yield Fund, TD Global Equity Focused Fund, TD Global Capital Reinvestment Fund, TD International Equity Focused Fund, TD International Equity Fund, TD China Income & Growth Fund, TD Fixed Income Pool, TD Risk Management Pool, TD Canadian Equity Pool, TD Global Equity Pool, TD Tactical Pool, TD Alternative Risk Focused Pool and TD Alternative Commodities Pool

Private-EM Series: TD U.S. Capital Reinvestment Fund, TD U.S. Mid-Cap Growth Fund, and TD Emerging Markets Fund

Advisor Series: TD U.S. Equity Pool

For other series of the TD Mutual Fund Trusts, TDAM pays all of the operating expenses (including services provided by TDAM or its affiliates), other than costs and expenses associated with: all taxes; borrowing; the IRC; compliance with any new governmental and regulatory requirements, and new types of costs or expenses.

(b) TD Managed Assets Program Portfolios

Except for the TD Managed ETF Portfolios, all operating expenses of the TD Managed Assets Program Portfolios (including for services provided by TDAM or its affiliates) are paid for by TDAM, including cost of the IRC, recordkeeping and communication costs, custodial, legal, audit and filing fees, bank charges, borrowing costs, and all taxes on such costs.

For the TD Managed ETF Portfolios, TDAM pays certain operating expenses. Each TD Managed ETF Portfolio is responsible for paying expenses associated with borrowing, the IRC, compliance with any new governmental and regulatory requirements, new types of costs or expenses, and all taxes on such costs and expenses.

Taxes on Expenses

The Funds also pay applicable goods and services tax and harmonized sales tax at a blended rate to TDAM on management fees, administration fees and certain operating expenses based on the province or territory of residence of the investors in each series of the Funds, which are included with the respective expense in the Statements of Comprehensive Income.

Waived Expenses

TDAM, at its discretion, may waive or absorb a portion of the expenses otherwise payable by the Funds. These waivers or absorptions may be terminated at any time without notice to unitholders. The amount of expenses waived or absorbed is disclosed in the Statements of Comprehensive Income as Waived Expenses, where applicable.

The Accrued Liabilities in the Statements of Financial Position represents the amount of management fees, administration fees and operating expenses (including applicable taxes) payable to TDAM by the Funds as at the reporting period end.

Brokerage Commissions and Soft Dollars

Brokerage commissions (including other transaction costs) paid on securities transactions and amounts paid to related parties of The Toronto-Dominion Bank for brokerage services provided to the Funds for the reporting periods ended December 31, 2024 and 2023, where applicable, are disclosed in the Fund-Specific Notes.

Client brokerage commissions are used as payment for order execution services and/or research services. The portfolio advisers or TDAM may select brokers including its affiliates, who charge a commission in excess of that charged by other brokers ("soft dollars") if they determine in good faith that the commission is reasonable in relation to the order execution and research services utilized.

For debt instruments traded in the over-the-counter markets where client brokerage commissions are not charged, soft dollars or client brokerage commissions are not generated. For equities or other securities where client brokerage commissions are charged, the soft dollar portion of the amount paid or payable for goods and services other than order execution for the Funds is not generally ascertainable. Any ascertainable soft dollar value received under the soft dollar arrangement entered into by the portfolio advisers or TDAM, where applicable, is disclosed in the Fund-Specific Notes.

7. Taxation

The Funds qualify or intend to qualify as mutual fund trusts under the *Income Tax Act* (Canada) ("Tax Act"), unless otherwise disclosed in the Fund-Specific Notes. All or substantially all of the net investment income and sufficient amounts of net capital gains realized in any taxation year are distributed to unitholders such that no income tax is payable by the Funds, except that in certain circumstances, a Fund that is not a mutual fund trust may become liable to pay alternative minimum tax under the Tax Act. As a result of the distributions, the Funds have determined that they are in substance not taxable under Part I of the Tax Act and therefore, do not record income taxes in the Statements of Comprehensive Income nor do they recognize any deferred tax assets or liabilities in the Statements of Financial Position. The Funds' capital and/or non-capital losses carry forward, where applicable, are provided in the Fund-Specific Notes. Capital losses have no expiry. Non-capital losses can be carried forward for up to twenty years.

The Funds may incur withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are reported as Tax Reclaims (Withholding Taxes) in the Statements of Comprehensive Income.

8. Financial Risk Management

Financial Risk Factors

Each Fund is exposed to a variety of financial risks: these may include market risk (including interest rate risk, currency risk, and other price risk), credit risk, liquidity risk, concentration risk and leverage risk. All investments present a risk of loss of capital.

Notes to the Financial Statements

TDAM seeks to reduce financial risks by employing and overseeing professional and experienced portfolio advisers that regularly monitor the Funds' positions and market events and diversify investment portfolios within the constraints of each Fund's investment objectives, investment strategies and applicable TDAM policies and procedures (collectively referred to as "Investment Restrictions").

If a Fund invests in Underlying Funds, TDAM seeks to reduce financial risks by diversifying investments across the three main asset classes: money market investments for safety, bonds for income and equity investments for growth, where applicable. Since different types of investments tend to move independently from one another, positive performance in one asset class may help to offset negative performance in another, thereby reducing volatility and overall risk in the long-term.

The Funds are managed in accordance with their respective Investment Restrictions.

(a) Market Risk

(i) Interest Rate Risk

Interest rate risk arises from the possibility that changes in interest rates will affect the future cash flows or the fair values of interest-bearing investments.

A Fund's exposure to interest rate risk is concentrated in its investments in debt instruments (such as bonds and debentures) and interest rate derivative instruments, if any. Short-term investments, currencies and other assets and liabilities are short-term in nature and/or non-interest bearing and not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates.

If a Fund invests in Underlying Funds, it is exposed to indirect interest rate risk to the extent of the interest-bearing financial instruments held by the Underlying Funds. A Fund's direct exposure to interest rate risk, where significant, is disclosed in the Fund-Specific Notes. Where a Fund invests in a single Underlying Fund, the direct and indirect exposure to interest rate risk, where significant, is disclosed in the Fund-Specific Notes.

(ii) Currency Risk

A Fund may hold financial instruments denominated in currencies other than its functional currency. It is therefore exposed to currency risk, as the value of the financial instruments denominated in other currencies will fluctuate due to changes in the foreign exchange rates of those currencies in relation to the Fund's functional currency.

Where a Fund invests in any Underlying Funds, it is exposed to indirect currency risk in the event that the Underlying Funds invest in financial instruments that are denominated in a currency other than the Underlying Funds' functional currency.

A Fund and/or its Underlying Funds may enter into foreign exchange forward contracts for hedging purposes to reduce its foreign currency exposure or to establish exposure to foreign currencies.

A Fund's direct exposure to currency risk (including monetary and non-monetary instruments), where significant, is disclosed in the Fund-Specific Notes. Where a Fund invests in a single Underlying Fund, the direct and indirect exposure to currency risk (including monetary and non-monetary instruments), where significant, is disclosed in the Fund-Specific Notes.

(iii) Other Price Risk

Other price risk is the risk that securities will fluctuate in value because of changes in market prices (other than those arising from interest rate risk or currency risk). TDAM seeks to reduce this risk through its Investment Restrictions.

In determining each Fund's sensitivity impact from exposure to other price risk, a historical beta may be used when applicable. Historical beta, a measure of the sensitivity of a fund's returns to market returns, is generally derived from comparing 36 months of returns between a fund and its benchmark. As such, beta inherently includes effects previously reflected in the interest rate risk and currency risk disclosures. Historical beta may not be representative of future beta.

Where a Fund invests in a single Underlying Fund, it is exposed to indirect other price risk arising from the Underlying Fund's investments. As a result, other price risk, reflecting this indirect exposure, is provided in the Fund-Specific Notes.

Where a Fund invests in several Underlying Funds, its exposure to other price risk includes all investments in Underlying Funds. A Fund's direct exposure to other price risk, where applicable, is disclosed in the Fund-Specific Notes.

Except for written call options and short futures contracts, the maximum risk of loss on certain derivative contracts is equal to their notional values. Possible losses from written call options and short futures contracts can be unlimited.

(b) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss to the other party by failing to discharge an obligation. Where applicable, a Fund's main credit risk concentration is in debt instruments and derivative instruments it holds. A Fund's exposure to credit risk is the risk that an issuer of debt instruments or a counterparty to derivative instruments will be unable to pay amounts in full when due. All transactions in listed securities are settled or paid for upon delivery using approved brokers. The risk of default with a broker is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation.

A Fund may be exposed to credit risk from the use of counterparties for foreign exchange forward contracts. Where applicable, this risk is minimized by:

- (i) using counterparties with a minimum credit rating of A by S&P Global Ratings ("S&PGR") or an equivalent rating from another recognized credit rating agency;
- (ii) limiting the term of the foreign exchange forward contracts to a maximum of 365 days; and,
- (iii) limiting the mark-to-market exposure to any one counterparty to 10 percent of the portfolio value.

A Fund may also be exposed indirectly to credit risk if it invests in Underlying Funds in the event that the Underlying Funds invest in debt instruments or derivatives.

The Funds and their Underlying Funds managed by TDAM only buy and hold short-term notes with a minimum of R-1 Low credit rating by DBRS Limited or an equivalent rating from another recognized credit rating agency.

Notes to the Financial Statements

A Fund's direct exposure to short-term notes, debt instruments and/or derivative instruments, by ratings categories, where applicable, is disclosed in the Fund-Specific Notes. Where a Fund invests in a single Underlying Fund, the direct and indirect exposure to short-term notes, debt instruments and/or derivative instruments, where applicable, is disclosed by rating categories in the Fund-Specific Notes.

Certain Funds and the Underlying Funds held by the Funds may also engage in securities lending transactions. For these funds that are managed by TDAM, the securities lending transactions are with counterparties that have a minimum credit rating of A by S&PGR or an equivalent rating from another credit agency. The value of cash or securities held as collateral by these funds in connection with these transactions is at least 102 percent of the fair value of the securities loaned. The collateral and loaned securities are marked to market on each business day. The aggregate fair value of the securities loaned, together with repurchase transactions, are limited to 50 percent of each fund's NAV determined immediately after the fund enters into any such transaction. Information about the fair values of securities lent and collateral held and securities lending income earned, where applicable, is disclosed in the Fund-Specific Notes.

(c) Liquidity Risk

Liquidity risk is defined as the risk that a fund may not be able to settle or meet its obligations on time or at a reasonable price. A fund's exposure to this risk is concentrated in the daily cash redemptions of redeemable units. The Funds primarily invest in securities that are traded in active markets and can be readily disposed of. In addition, the Funds retain sufficient cash and cash equivalents to maintain liquidity, and have the ability to borrow up to 5 percent of their respective NAV for the purpose of funding redemptions.

All non-derivative financial liabilities, other than redeemable units outstanding, are due in less than 3 months.

On May 16, 2022, Refinitiv Benchmark Services (UK) Limited, the administrator of the Canadian Dollar Offered Rate (CDOR), announced the cessation of the calculation and publication of all tenors of CDOR immediately following a final publication on June 28, 2024. TDAM did not notice any significant liquidity or valuation impact on the Funds from the CDOR transition.

(d) Concentration Risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is geographical location, security type or industry sector. A Fund's concentration risk is disclosed in the Fund-Specific Notes.

(e) Leverage Risk

Leverage risk is the risk that an adverse change in the value or level of the underlying asset, rate or index to which the fund has leveraged exposure, may amplify losses compared to those that would have been incurred if the fund had not used any leverage and could result in losses that are greater than the amount invested.

TD Alternative Risk Focused Pool, TD Alternative Commodities Pool and TD Alternative Long/Short Commodities Pool are alternative mutual funds, in accordance with National Instrument 81-102, "*Investment Funds*", and are permitted to leverage their assets as part of their investment strategy through the use of cash borrowing, physical short sales and/or specified derivatives, at amounts that may exceed the NAV of these funds. Information on these funds' use of leverage is disclosed in the Fund-Specific Notes.

9. Capital Risk Management

Units issued and outstanding represent the capital of the Funds. The Funds do not have any specific capital requirements on the subscription and redemption of units, other than certain minimum subscription requirements. Changes in the Funds' capital during the reporting periods are reflected in the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units. TDAM is responsible for managing the capital of the Funds in accordance with each Fund's investment objectives and for managing liquidity in order to meet redemption requests.

If applicable, the most recent financial statements of the Underlying Funds managed by TDAM are available, without charge, by writing to TD Asset Management Inc., P.O. Box 100, 66 Wellington Street West, TD Bank Tower, Toronto-Dominion Centre, Toronto, Ontario, M5K 1G8, or by visiting our website at www.td.com/ca/en/asset-management or the SEDAR+ website at www.sedarplus.ca.

Currency codes used throughout the report:

Currency Code	Description	Currency Code	Description	Currency Code	Description
AED	UAE Dirham	HKD	Hong Kong Dollar	PHP	Philippine Peso
ARS	Argentine Peso	HUF	Hungarian Forint	PKR	Pakistan Rupee
AUD	Australian Dollar	IDR	Indonesian Rupiah	PLN	Polish Zloty
BRL	Brazilian Real	ILS	Israeli Shekel	QAR	Qatari Riyal
CAD/C\$	Canadian Dollar	INR	Indian Rupee	RON	Romanian Leu
CHF	Swiss Franc	JOD	Jordanian Dinar	RUB	Russian Ruble
CLP	Chilean Peso	JPY	Japanese Yen	SAR	Saudi Riyal
CNY/CNH	Chinese Renminbi	KRW	South Korean Won	SEK	Swedish Krona
COP	Colombian Peso	LKR	Sri Lankan Rupee	SGD	Singapore Dollar
CZK	Czech Koruna	MAD	Moroccan Dirham	THB	Thai Baht
DKK	Danish Krone	MXN	Mexican Peso	TRY	Turkish Lira
EGP	Egyptian Pound	MYR	Malaysian Ringgit	TWD	New Taiwan Dollar
EUR	Euro	NOK	Norwegian Krone	USD/US\$	United States Dollar
GBP	British Pound	NZD	New Zealand Dollar	ZAR	South African Rand

Source: London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2024. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®", "Russell®", and "FTSE Russell®" are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.

TD Mutual Funds, TD Pools and the TD Managed Assets Program portfolios are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto-Dominion Bank and are available through authorized dealers.

TD ETFs are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto-Dominion Bank.

Epoch Investment Partners, Inc. operates in the United States and is an affiliate of TD Asset Management Inc. TD Asset Management Inc. operates in Canada. Both are wholly-owned subsidiaries of The Toronto-Dominion Bank.

®The TD logo and other TD trademarks are the property of The Toronto-Dominion Bank or its subsidiaries.